neuroscienceCME - Don't Snooze on the Latest Evidence on Excessive Daytime Sleepiness in OSA and Narcolepsy: An Expert-Guided Tour of the Sleep 2019 Annual Meeting

PLEASE READ THESE TERMS OF SERVICE CAREFULLY. IF YOU DO NOT AGREE TO THESE TERMS OF SERVICE, YOU WILL NOT BE ABLE TO CREATE A USER PROFILE FOR THIS WEBSITE. IF YOU AGREE TO THESE TERMS OF SERVICE ONCE, THEY WILL APPLY TO ALL FUTURE USES OF THIS WEBSITE. FROM TIME TO TIME, CME OUTFITTERS, LLC, ("CMEO") MAY CHANGE THESE TERMS OF SERVICE, IN WHICH CASE YOU WILL BE ASKED TO AGREE TO SUCH NEW TERMS IN ORDER TO ACCESS OUR WEBSITE.

All of the information on this website is meant for adults who are licensed healthcare professionals. While we hope you find it helpful, you should remember that it is not a substitute for your own clinical judgement as a healthcare professional. The information provided on this website is designed to build upon existing knowledge and enhance clinical practice and is not meant to substitute for the independent medical judgement of healthcare professionals relative to diagnostic and treatment options for a specific patient's medical condition(s). You should exercise your professional judgement in evaluating the information on this website, and we encourage you to confirm the information contained on our website with other sources before undertaking any treatment based on it. Clinicians or other healthcare professionals should not utilize any diagnostic procedures or treatments without evaluation of their patients' conditions, and of possible contraindications or risks, and without a review of any applicable manufacturer's product information and comparison with the recommendations of other authorities.

If you are a consumer who chooses to use the professional-level information on this website, you should not rely on such information as professional medical advice or use it to replace any relationship with your physician or other qualified healthcare professional. Consumers should always consult their physicians or, in serious cases, seek immediate assistance from emergency personnel, before making any decisions about medications and/or treatments.

By becoming a registered user of this website, you are automatically subscribed to newsletter and email lists that provide news, educational offerings, and information of interest to the intended audience. Subscriber information is never loaned, given, or sold to outside entities. You may unsubscribe from any of these vehicles at any time without affecting your status as a registered user of this website. CMEO reserves the right to disable your user account at our sole discretion.

ALL DATA, INFORMATION, AND OTHER MATERIALS AVAILABLE ON OR THROUGH THIS WEBSITE ARE PROVIDED "AS IS" AND "WITH ALL FAULTS" WITHOUT REPRESENTATIONS, WARRANTIES, OR INDEMNITIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY ARISING BY CUSTOM OR USAGE IN THE TRADE. CMEO MAKES NO WARRANTIES OR REPRESENTATIONS AS TO THE ACCURACY, COMPLETENESS, RELIABILITY, OR AVAILABILITY OF ANY INFORMATION PRESENTED ON THIS WEBSITE. THERE IS NO WARRANTY AGAINST INTERFERENCE WITH YOUR ENJOYMENT OF THE INFORMATION ON THIS WEBSITE OR AGAINST INFRINGEMENT. FURTHER, CMEO MAKES NO WARRANTIES OR REPRESENTATIONS THAT ITS WEBSITE SERVICE WILL BE UNINTERRUPTED OR ERROR-FREE OR THAT ANY FILES DOWNLOADED THROUGH THIS WEBSITE WILL BE FREE OF VIRUSES OR OTHER CONTAMINATING CAPABILITIES. ALL WARRANTIES ARE EXPRESSLY DISCLAIMED. THE ENTIRE RISK AS TO SATISFACTORY QUALITY, PERFORMANCE, ACCURACY, AND EFFORT IS WITH YOU.

CMEO SHALL NOT BE LIABLE FOR ANY ERRORS OR OMISSIONS IN THE INFORMATION PROVIDED ON THIS WEBSITE OR FOR ANY DAMAGES RESULTING FROM THE USE OF OR INABILITY TO USE THE INFORMATION OR SERVICES PROVIDED ON THIS WEBSITE. IN NO EVENT SHALL CMEO BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR PUNITIVE DAMAGES OR FOR ANY ATTORNEYS' FEES OR COSTS. IN NO EVENT SHALL CMEO'S MAXIMUM LIABILITY TO YOU OR ANYONE CLAIMING BY OR THROUGH YOU UNDER ANY THEORY (INCLUDING BUT NOT LIMITED TO FRAUD, MISREPRESENTATION, BREACH OF CONTRACT, PERSONAL INJURY, PRODUCTS LIABILITY, OR FAILURE TO WARN) EXCEED TEN THOUSAND DOLLARS ($10,000.00).

The opinions, recommendations, and perspectives expressed via the CMEO services are those of the authors only and do not necessarily reflect the opinions, ideas, or recommendations of their affiliated institutions, the CMEO editorial boards and consultants, and/or the commercial supporters of any of the foregoing.

All trademarks, service marks, and logos on this website are the trademarks, service marks, and logos of their respective owners, whether or not they appear with the trademark symbol. The content of this website, including all images, text, programming, and multimedia files, is copyrighted and may not be reproduced, modified, or otherwise used without the express written permission of the respective owners. It is the policy of CMEO to enforce its intellectual property rights to the fullest extent permitted under law.

CMEO controls this website from within the State of Maryland. These Terms of Service are entered into in the State of Maryland, United States of America, and shall be governed by, construed, and enforced under the substantive laws of the State of Maryland, without regard to its conflict of laws, applicable federal law, the regulations of the Federal Communications Commission, the laws and regulations of the state or country where the information is viewed, or international treaties. You and CMEO agree that the sole and exclusive jurisdiction and venue for any litigation arising from or relating to the use of this website shall be the Circuit Court for Montgomery County, Maryland. You and CMEO hereto submit to the exclusive jurisdiction of such Court and waive any jurisdictional, venue, or inconvenient forum objections to such courts. You and CMEO agree to accept service of process pursuant to Maryland Rules and procedures.

YOU AND CMEO EXPRESSLY WAIVE THE RIGHT TO A TRIAL BY JURY AND THE RIGHT TO PURSUE ON A CLASS BASIS ANY CONTROVERSY OR CLAIM AGAINST EACH OTHER.

Activity Not Available

The activity "Don't Snooze on the Latest Evidence on Excessive Daytime Sleepiness in OSA and Narcolepsy: An Expert-Guided Tour of the Sleep 2019 Annual Meeting" is currently unavailable.

Please refer to the Educational Activities Menu for a complete list of available offerings.

A.	0% of the time
B.	1% - 25% of the time
C.	26% - 50% of the time
D.	76% - 100% of the time

A.	0% of patients
B.	1% - 25% of patients
C.	26% - 50% of patients
D.	51% - 75% of patients
E.	76% - 100% of patients

A.	Extremely confident
B.	Confident
C.	Somewhat confident
D.	Not confident at all

A.	Extremely confident
B.	Confident
C.	Somewhat confident
D.	Not confident at all

A.	50% of patients and 25% of physicians
B.	97% of patients and 73% of physicians
C.	17% of patients and 82% of physicians
D.	87% of patients and 92% of physicians
E.	I don’t know

A.	Its mechanism of action is similar to other therapies for EDS, but its safety profile is better.
B.	It has recently been approved to improve wakefulness in adults with EDS associated with narcolepsy and OSA.
C.	It produced sustained improvements in functional status, work productivity, and quality of life in both narcolepsy and OSA.
D.	It decreased scores on the Epworth Sleepiness Scale compared to placebo from baseline to week 12.
E.	I don't know

A.	It was shown to effectively reduce EDS in OSA.
B.	It is a dual-acting dopamine and norepinephrine reuptake inhibitor.
C.	Recent clinical trial findings on novel therapies for EDS are conflicting and warrant further investigation.
D.	Using the Pittsburgh Sleep Quality Index (PSQI), sleep quality was rated significantly higher for those treated with pitolisant compared to placebo.
E.	I don’t know.

A.	Traditional therapies for EDS in narcolepsy and OSA are effective but produce serious adverse events.
B.	Novel therapies for EDS that target different mechanisms of action are capable of producing sustained, long-term effects.
C.	Recent clinical trial findings on novel therapies for EDS are conflicting and warrant further investigation.
D.	EDS is a debilitating symptom that impacts quality of life and work function, but social functioning is only minimally impaired.
E.	I don’t know.